Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 10752667Search this ID in NIH RePORTER
- ScienceDex PI coverage
- FY2024 onlyCareer claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2024 award categories
- OTHER BASIC SCIENCES
NIH Funding · FY2024
Linked Award Amount
$1.5M
Full award amounts, FY2024
Award Records
3
Records listing this PI
Award-Linked Rank
#8,463
By linked amount among FY2024 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage
Award data coverage
ScienceDex currently has one fiscal year of PI ranking data for this record. This does not establish the first NIH award or current employer.
Single fiscal year on record (FY2024): $1.5M in linked award amounts across 3 award records · Award-linked rank #8463.
FY2024 award records by amount
NIH award records listing Ohannes Kevork Melemedjian as a PI. Multi-PI records show the full award amount for context.
- 4R01DE029074-02R01Novel target identification for treatment of chronic overlapping pain using multimodal brain imaging$740.1Kaward amount
- 4R01CA249939-02R01Identification of novel targets for the treatment of chemotherapy-induced painful peripheral neuropathy$388.8Kaward amount
- 4R01NS116759-02R01Validating ASCT2 for the Treatment of Chronic Postsurgical Pain$386.3Kaward amount
Award organization
Organizations that administered FY2024 awards listing Ohannes Kevork Melemedjian as a PI.
FY2024 award administered by University of Maryland Baltimore (MD).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardUniversity of Maryland Baltimore
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2024Entered Top 50% NationallyRanked #8463
Shared-award investigators
Other investigators listed on at least one of the same NIH award records as Ohannes Kevork Melemedjian.